Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 12Oropharyngeal Neoplasms 12Lung Neoplasms 9Carcinoma 8Mouth Neoplasms 7Laryngeal Neoplasms 7Mesothelioma, Malignant 6Hypopharyngeal Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Uterine Cervical Neoplasms 5Nasopharyngeal Carcinoma 5Urinary Bladder Neoplasms 4Pancreatic Neoplasms 4Triple Negative Breast Neoplasms 3Salivary Gland Neoplasms 3Lymphoid Interstitial Pneumonia 3Gallbladder Neoplasms 3Testicular Neoplasms 2Seminoma 2Medulloblastoma 2Ganglioneuroblastoma 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Breast Neoplasms 2Adenocarcinoma of Lung 2Wilms Tumor 1Vulvar Neoplasms 1Vaginal Neoplasms 1Tongue Neoplasms 1Teratoma 1

Interventions

Magnetic Resonance Spectroscopy 49enzalutamide 46apalutamide 36Specimen Handling 34Androgen Antagonists 30Abiraterone Acetate 29Radiosurgery 27Prednisone 26darolutamide 25Docetaxel 23Pluvicto 22abiraterone 20Radiotherapy 19Biopsy 17Leuprolide 15relugolix 11gallium 68 PSMA-11 11acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11Surveys and Questionnaires 11Radiation 112-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 11Standard of Care 10Nivolumab 10cabazitaxel 9X-Rays 9Triptorelin Pamoate 9bicalutamide 8Carboplatin 8pembrolizumab 7olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Platinum × 90 days × Clear all
NCT06303713 2026-04-08

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
37 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡